These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16407687)

  • 1. Fibrates in combination with statins in the management of dyslipidemia.
    Jacobson TA; Zimmerman FH
    J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopathy with statin-fibrate combination therapy: clinical considerations.
    Jacobson TA
    Nat Rev Endocrinol; 2009 Sep; 5(9):507-18. PubMed ID: 19636324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Brinton EA
    Curr Atheroscler Rep; 2008 Feb; 10(1):25-32. PubMed ID: 18366982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug combinations: statins and fibrates].
    Xavier HT
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():34-5. PubMed ID: 16400396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between statins and fibrates.
    Corsini A; Bellosta S; Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):44K-49K; discussion 34K-35K. PubMed ID: 16291014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrates: where are we now?
    Seth Loomba R; Arora R
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety considerations with fibrate therapy.
    Davidson MH; Armani A; McKenney JM; Jacobson TA
    Am J Cardiol; 2007 Mar; 99(6A):3C-18C. PubMed ID: 17368275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of statins and fibrates in the management of cardiovascular risk.
    Fiévet C; Staels B
    Curr Opin Lipidol; 2009 Dec; 20(6):505-11. PubMed ID: 19829109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
    Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
    Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.